Affiliations: [a] Department of Hematology, Wuxi People’s Hospital, Nanjing Medical University, Wuxi, Jiangsu, China | [b] Department of Clinical Laboratory, Wuxi People’s Hospital, Nanjing Medical University, Wuxi, Jiangsu, China
Correspondence:
[*]
Corresponding author: Hongfeng Guo, Department of Hematology, Wuxi People’s Hospital, Nanjing Medical University, 299 Qingyang Road, Wuxi, Jiangsu 214023, China. Tel.: +86 510 8535 0201; E-mail: guohongf2000@aliyun.com.
Note: [1] These authors contributed equally to this work.
Abstract: BACKGROUND: The Controlling Nutritional Status (CONUT) score, a novel immuno-nutritional index, was reported as a predictor of overall survival (OS) in some tumors. OBJECTIVE: We aimed to investigate the association between baseline CONUT Score and clinical outcomes in patients with multiple myeloma (MM). METHODS: We performed a retrospective analysis of 245 patients with MM. The CONUT score was determined prior to therapy. RESULTS: Among the entire cohort, the complete remission rate was markedly higher in the low-CONUT (⩽ 3) group compared to the mid-CONUT (4–9) group or high-CONUT (> 9) group (44.1% vs 25.8%, P= 0.039; 44.1% vs 12.5%, P= 0.002). Patients with CONUT score > 9 had significant poor prognosis, and CONUT score ⩽ 3 group showed better survival outcome than other groups in OS (P< 0.001). Besides, we stratified the patients by combining International Staging System (ISS) stage and CONUT score in a model, and found that CONUT score could improve the prognostic impact of ISS stages on OS. In multivariate analysis, older age (⩾ 70 years) and a high CONUT score (⩾ 4) were independent prognostic risk factors for OS. CONCLUSIONS: The CONUT score was a predictor of OS in MM patients especially in cases with both low ISS staging and CONUT score. The baseline CONUT score may be an early and practical indicator of the efficacy of anti-myeloma treatment.
Keywords: Multiple myeloma, controlling nutritional status score, prognostic
